Tauns Laboratories (TSE:197A) Debt-to-Revenue : N/A (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tauns Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Tauns Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was 円5,232 Mil. Tauns Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was 円8,083 Mil. Tauns Laboratories's annualized Revenue for the quarter that ended in Dec. 2024 was 円0 Mil.

Tauns Laboratories Debt-to-Revenue Historical Data

The historical data trend for Tauns Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tauns Laboratories Debt-to-Revenue Chart

Tauns Laboratories Annual Data

Trend

Jun22

Jun23

Jun24

Debt-to-Revenue

0.28

0.41

0.52

Tauns Laboratories Quarterly Data
	Jun22	Jun23	Mar24	Jun24	Dec24
Debt-to-Revenue	N/A	N/A	N/A	1.16	N/A

Competitive Comparison of Tauns Laboratories's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tauns Laboratories's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tauns Laboratories's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Tauns Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Tauns Laboratories's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5232	+	4307)	/	18434.863
	=	0.52

Tauns Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5232	+	8083)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Tauns Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tauns Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tauns Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tauns Laboratories Inc (TSE:197A) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325

Website

https://www.tauns.co.jp/en

Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.

Tauns Laboratories Headlines

No Headlines